Efficacy and safety of mitoxantrone hydrochloride liposome-containing regimens in treating refractory/relapsed acute myeloid leukemia
Abstract Background Despite the poor prognosis for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML), an optimal treatment strategy remains undefined. Mitoxantrone (MIT) is widely used to treat R/R AML. Methods This prospective, single-center, open-label study assessed the efficac...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer
2025-05-01
|
| Edice: | Discover Oncology |
| Témata: | |
| On-line přístup: | https://doi.org/10.1007/s12672-025-02526-y |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
